Consolidation durvalumab is effective and safe for post-CCRT unresectable stage III NSCLC in clinical practice, but EGFR mutations are an unfavorable factor for consolidation durvalumab. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.